ResearcherHumboldt-Universität zu BerlinActive in the last 2 years
François Schneider
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 2 papers
Papers 5
- Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. First author DOI 10.1002/cam4.71490↗
- The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pan… Co-author DOI 10.1016/j.ejca.2025.116189↗
- Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. Co-author DOI 10.1186/s12935-025-03969-7↗
- Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last Decade. First author DOI 10.3390/cancers15082367↗
- Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients-A Single Center Analysis of 2323 Patien… First author DOI 10.3390/jcm12113656↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher Neumann · 5 shared papers, 2023–2026 · strength 1.00
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Uwe Pelzer · 5 shared papers, 2023–2026 · strength 1.00
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Matthäus Felsenstein · 4 shared papers, 2023–2026 · strength 0.83
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Marcus Bahra · 3 shared papers, 2025–2026 · strength 0.67
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Mihnea Paul Dragomir · 3 shared papers, 2025–2026 · strength 0.67
- Paper Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study. DOI 10.1002/cam4.71490↗
- Paper The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic stat… DOI 10.1016/j.ejca.2025.116189↗
- Paper Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. DOI 10.1186/s12935-025-03969-7↗
- Katharina Wansch · 2 shared papers, 2025–2026 · strength 0.43
- Florian Dölvers · 2 shared papers, 2025–2026 · strength 0.43
- Christian Benzing · 1 shared paper, 2023 · strength 0.17
- Thomas Malinka · 1 shared paper, 2023 · strength 0.17
- Uli Fehrenbach · 1 shared paper, 2023 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.